Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ADENUIRC is substantial. |
Clinical Added Value
| minor |
The Transparency Committee considers that ADENURIC provides a minor improvement in actual benefit (level IV) in the management of symptomatic chronic hyperuricaemia compared to the current therapeutic strategy based on allopurinol. |
eNq1mN9v2jAQx9/5K6K8kwAdhU6BamOwIbUao0Wb9lKZ5ChmwU7PNj/2188hVIPJUYfBj7Gd7519dx+fHN1ulqm3AhSUs45fD2q+ByzmCWXPHX/yOKi2/dtuJVqQFTlY1gpqQb3he3FKhOj4+WwwBcJE8OP+7hPo/wH9bsWL+HQBsTxapyRNgy9EzO9Jlq/xohWnibcEOedJx8+U3I16kZCoveiuOf4SGYkhCvcjh7OLp3eH41GYi/2HqhKAd4Q9G0WBWWnGChGY7BEJzxy3Jf5eWWlTMQbBFcYwInI+Qr6iCSRGEzOSCrAyMlsnD4CrFGRuxCgeLuKlsBInC7IZw8vQ7PQHPduTG1mtVeutVrvRbDRqN7WrtpUpPDgqcxT0JsL4qd1oterXIbCQJMAU0tgyNiOOkqSOokJF7zixHNlBeHkz+gkVWUq2wUJktkdFkOhpQF3+7jaS7+ARNZBSfWb/6DOVpuGJXk/2uHDkcU6jHldMllBjMLY9iB5nEjblEbUDndzsc5GCuJzsb87MkB+paWpZmxppGjoKhJyMh+VEuyQMPhIBE3RHg++UJXwtLk+Zw6g68j7bgdIommFSf2rctK/rzaZ1Ef3UKVRyw/QV8gxCzR8qzsHKkM34uUDRWWmWes3Ji6Xjrs/hMUmhpNOpWrJF5+FrY+Ys091VUTFhFP3cf7RNj28KcPuw+zRK06TzGlg77rqAuc7FUr9Pz+yiwJ20wArN4JhLmYn3Ybher4M5EVVB9CkFM7w42A/uUncNuJMLu2hgCjg6cn1a3HqnRci20N660s9tU/f/79thow2JCs6IRcFkZ+Qc9i8P4789qjO3R0f0cGdm108SSTlz1eeoqVHxLPzrsLIBaj58nc1oyXtIaVpGYfEW061EYf4O0638Aeex5RI=
z4g2DdndKuWt44TC
